Alex Graham

Engineering teams switch to cloud-native tools for what it gets them: more speed, running simulations and studies in parallel instead of queuing for a workstation or cluster, and broader access with more flexibility across their organizations. Those have been the reasons for years. But now there is another, and it is quickly becoming the more urgent: AI. AI is starting to touch nearly every step of a simulation project.

Bioliberty is one of those Scottish deep-tech companies that is easy to under-notice. It’s quiet on social media, doesn’t push much into the tech press, is FDA-listed, ships a physical product manufactured in Fife, and commercialises through American healthcare rather than the NHS. Readers who follow Scottish medtech closely will already have seen the March 2026 Series A headlines.

Robotics teams are under the same pressure as everyone else building hardware right now: less time to prove a design works. Automotive suppliers that used to have months to respond to an RFP now have weeks, medical device makers race for first-to-market approval, and every legged, wheeled, or 3D-printing robot still has to pass its compliance tests before it ships.